Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001703057-26-000020
Filing Date
2026-04-29
Accepted
2026-04-29 14:07:23
Documents
17
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 DEF 14A abcl-20260429.htm   iXBRL DEF 14A 743424
3 abcl-20260429_g1.jpg GRAPHIC 21340
4 abcl-20260429_g2.jpg GRAPHIC 63283
5 abcl-20260429_g3.jpg GRAPHIC 91184
6 abcl-20260429_g4.jpg GRAPHIC 248078
7 abcl-20260429_g5.jpg GRAPHIC 243020
  Complete submission text file 0001703057-26-000020.txt   2976685

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT abcl-20260429.xsd EX-101.SCH 918
20 EXTRACTED XBRL INSTANCE DOCUMENT abcl-20260429_htm.xml XML 152755
Mailing Address 150 W 4TH AVENUE VANCOUVER A1 V5Y 1G6
Business Address 150 W 4TH AVENUE VANCOUVER A1 V5Y 1G6 (604) 559-9005
AbCellera Biologics Inc. (Filer) CIK: 0001703057 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39781 | Film No.: 26913890
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)